Journal of Vaccine Research 2024, Vol.14, No.2, 40-53 http://medscipublisher.com/index.php/jvr 50 Bernasconi V., Bernocchi B., Ye L., Le M., Omokanye A., Carpentier R., Schon K., Saelens X., Staeheli P., Betbeder D., and Lycke N., 2018, Porous nanoparticles with self-adjuvanting M2e-fusion protein and recombinant hemagglutinin provide strong and broadly protective immunity against influenza virus infections, Frontiers in Immunology, 9: 2060. https://doi.org/10.3389/fimmu.2018.02060 PMid:30271406 PMCid:PMC6146233 Bernstein D., Guptill J., Naficy A., Nachbagauer R., Berlanda-Scorza F., Feser J., Wilson P., Solórzano A., Wielen M., Walter E., Albrecht R., Buschle K., Chen Y., Claeys C., Dickey M., Dugan H., Ermler M., Freeman D., Gao M., Gast C., Guthmiller J., Hai R., Henry C., Lan L., McNeal M., Palm A., Shaw, D., Stamper C., Sun W., Sutton V., Tepora M., Wahid R., Wenzel H., Wohlbold T., Innis,B., García-Sastre A., Palese P., and Krammer F., 2019, Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial, The Lancet. Infectious Diseases, 20: 80-91. https://doi.org/10.1016/S1473-3099(19)30393-7 PMid:31630990 Cadorna-Carlos J., Nolan T., Borja-Tabora C., Santos J., Montalbán M., Looze F., Eizenberg P., Hall S., Dupuy M., Hutagalung Y., Pépin S., and Saville M, 2015, Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial, Vaccine, 33(21): 2485-2492. https://doi.org/10.1016/j.vaccine.2015.03.065 PMid:25843270 Carter D., Darby C., Lefoley B., Crevar C., Alefantis T., Oomen R., Anderson,S., Strugnell T., Cortés-Garcia G., Vogel T., Parrington M., Kleanthous H., and Ross T., 2016, Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses. Journal of Virology, 90: 4720-4734. https://doi.org/10.1128/JVI.03152-15 PMid:26912624 PMCid:PMC4836330 Cho A., and Wrammert J., 2016, Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine.. Current opinion in virology, 17: 110-115. https://doi.org/10.1016/j.coviro.2016.03.002 PMid:27031684 PMCid:PMC4940123 Chu K., Xu K., Tang R., Tian X., Hu J., Yang T., Li C., Hu Y., and Zeng, G., 2020, Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III study in healthy population aged≥ 3 years, Vaccine, 38(37): 5940-5946. https://doi.org/10.1016/j.vaccine.2020.06.071 PMid:32732142 Corder B.N., Bullard B.L., Poland G.A., and Weaver E.A., 2020, A decade in review: a systematic review of universal influenza vaccines in clinical trials during the 2010 decade, Viruses, 12(10): 1186. https://doi.org/10.3390/v12101186 PMid:33092070 PMCid:PMC7589362 Coughlan L., and Palese P., 2018, Overcoming barriers in the path to a universal influenza virus vaccine, Cell Host and Microbe, 24(1): 18-24. https://doi.org/10.1016/j.chom.2018.06.016 PMid:30001520 DiLillo D.J., Palese P., Wilson P.C., and Ravetch J.V., 2016, Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection, The Journal of Clinical Investigation, 126(2): 605-610. https://doi.org/10.1172/JCI84428 PMid:26731473 PMCid:PMC4731186 Eichelberger M.C., and Monto A.S., 2019, Neuraminidase, the forgotten surface antigen, emerges as an influenza vaccine target for broadened protection, The Journal of Infectious Diseases, 219(Supplement_1): S75-S80. https://doi.org/10.1093/infdis/jiz017 PMid:30715357 PMCid:PMC7325326 Ekiert D.C., and Wilson I.A., 2012, Broadly neutralizing antibodies against influenza virus and prospects for universal therapies, Current Opinion in Virology, 2(2): 134-141. https://doi.org/10.1016/j.coviro.2012.02.005 PMid:22482710 PMCid:PMC3368890 Feng D., Liu M., Zhang X., and Xu J., 2018, Research progress in broad neutralizing antibodies and universal vaccines against influenza A virus, Chinese Journal of Microbiology and Immunology, 782-789. Freyn A.W., da Silva J.R., Rosado V.C., Bliss C.M., Pine M., Mui B.L., Tam Y., Madden T., Ferreira L., Weissman D., Krammer F., Coughlan L., Palese P., Pardi N., and Nachbagauer R., 2020, A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice, Molecular Therapy, 28(7): 1569-1584. https://doi.org/10.1016/j.ymthe.2020.04.018 PMid:32359470 PMCid:PMC7335735
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==